<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0208357</article-id>
<article-id pub-id-type="publisher-id">PONE-D-18-25898</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive science</subject><subj-group><subject>Cognitive psychology</subject><subj-group><subject>Learning</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Cognitive psychology</subject><subj-group><subject>Learning</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Cognitive psychology</subject><subj-group><subject>Learning</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Learning and memory</subject><subj-group><subject>Learning</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Nervous system</subject><subj-group><subject>Central nervous system</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Nervous system</subject><subj-group><subject>Central nervous system</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Diagnostic radiology</subject><subj-group><subject>Magnetic resonance imaging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Imaging techniques</subject><subj-group><subject>Diagnostic radiology</subject><subj-group><subject>Magnetic resonance imaging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Radiology and imaging</subject><subj-group><subject>Diagnostic radiology</subject><subj-group><subject>Magnetic resonance imaging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive science</subject><subj-group><subject>Cognitive neuroscience</subject><subj-group><subject>Cognitive neurology</subject><subj-group><subject>Cognitive impairment</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive neuroscience</subject><subj-group><subject>Cognitive neurology</subject><subj-group><subject>Cognitive impairment</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Cognitive neurology</subject><subj-group><subject>Cognitive impairment</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Vascular medicine</subject><subj-group><subject>Blood pressure</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Cerebrovascular diseases</subject><subj-group><subject>Stroke</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Vascular medicine</subject><subj-group><subject>Stroke</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Animal studies</subject><subj-group><subject>Experimental organism systems</subject><subj-group><subject>Model organisms</subject><subj-group><subject>Rats</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Model organisms</subject><subj-group><subject>Rats</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Animal studies</subject><subj-group><subject>Experimental organism systems</subject><subj-group><subject>Animal models</subject><subj-group><subject>Rats</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Eukaryota</subject><subj-group><subject>Animals</subject><subj-group><subject>Vertebrates</subject><subj-group><subject>Amniotes</subject><subj-group><subject>Mammals</subject><subj-group><subject>Rodents</subject><subj-group><subject>Rats</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Brain</subject><subj-group><subject>Hippocampus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Brain</subject><subj-group><subject>Hippocampus</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>MMP-9 inhibitors impair learning in spontaneously hypertensive rats</article-title>
<alt-title alt-title-type="running-head">MMP-9 inhibitors impair learning</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-8817-6796</contrib-id>
<name name-style="western">
<surname>Raz</surname>
<given-names>Limor</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Yang</surname>
<given-names>Yi</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Thompson</surname>
<given-names>Jeffrey</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Hobson</surname>
<given-names>Sasha</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Pesko</surname>
<given-names>John</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Mobashery</surname>
<given-names>Shahriar</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Chang</surname>
<given-names>Mayland</given-names>
</name>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Rosenberg</surname>
<given-names>Gary</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Neurology, University of New Mexico, Albuquerque, New Mexico, United States of America</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>UNM Memory and Aging Center, University of New Mexico, Albuquerque, New Mexico, United States of America</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>AbbVie, Data and Statistical Sciences, North Chicago, Illinois, United States of America</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Arai</surname>
<given-names>Ken</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Massachusetts General Hospital/Harvard Medical School, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>One of the authors, John Pesko, is currently employed by AbbVie Inc. However, Dr. Pesko was not affiliated with AbbVie at the time of the study and the affiliation does not alter our adherence to PLOS ONE policies on sharing data and materials.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">Dr.liraz@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>13</volume>
<issue>12</issue>
<elocation-id>e0208357</elocation-id>
<history>
<date date-type="received">
<day>3</day>
<month>9</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>11</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-year>2018</copyright-year>
<copyright-holder>Raz et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0208357"/>
<abstract>
<p>Vascular cognitive impairment dementia (VCID) is a major cause of cognitive loss in the elderly. Matrix metalloproteinases (MMPs) are a family of proteases involved in remodeling the extracellular matrix in development, injury and repair. Blood-brain barrier (BBB) disruption due to inflammation mediated by MMPs is a mechanism of white matter injury. Currently there are no treatments besides the control of vascular risk factors. We tested two MMP-9 inhibitors that improved outcome in acute stroke: DP-460 and SB-3CT. We hypothesized that these inhibitors would have a beneficial effect in chronic stroke by reducing edema in white matter and improving behavioral outcomes. Spontaneously hypertensive stroke-prone rats (SHRSPs) with unilateral carotid artery occlusion (UCAO) fed a Japanese Permissive Diet (JPD) were used as a model of VCID. JPD was begun in the 12<sup>th</sup> week of life. Rats were treated with DP-460 (500 mg/kg) for 4 weeks, or SB-3CT (10 mg/kg) for 8 weeks, beginning at the UCAO/JPD onset. Rats treated with a dextrose or DMSO solution served as vehicle controls. Naïve SHRSPs on a standard diet served as sham control. Magnetic resonance imaging (MRI) analyses of the corpus callosum, external capsule, hippocampus and Morris water maze behavioral tests were conducted. We found an increase in body weight (p = 0.004) and blood pressure (p = 0.007) at 15 weeks with the DP-460 drug. SB-3CT increased body weight at 14 weeks (p = 0.015) and had significant but variable effects on blood pressure. Neither drug affected imaging parameters. Behavioral studies showed an impaired ability to learn with DP-460 (p&lt;0.001) and no effect on learning with SB-3CT. Unchanged MMP-9 levels were detected in DP-460-treated rats via gel zymography. Our findings suggest that MMPs are not major factors in white matter damage in the SHRSP model of VCID and that drugs that are relatively selective for MMP-9 can interfere with learning.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000065</institution-id>
<institution>National Institute of Neurological Disorders and Stroke</institution>
</institution-wrap>
</funding-source>
<award-id>RO1 NS045847-071A​</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Rosenberg</surname>
<given-names>Gary</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This study is funded by the National Institute of Health and awarded to Gary Rosenberg, PhD, RO1 NS045847-071A​. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="4"/>
<table-count count="2"/>
<page-count count="11"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the manuscript and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Vascular cognitive impairment dementia (VCID) is an important cause of dementia and an accelerator of cognitive decline in Alzheimer’s disease (AD).[<xref ref-type="bibr" rid="pone.0208357.ref001">1</xref>, <xref ref-type="bibr" rid="pone.0208357.ref002">2</xref>] Neuroinflammation is a major contributor to progressive injury to the white matter.[<xref ref-type="bibr" rid="pone.0208357.ref003">3</xref>, <xref ref-type="bibr" rid="pone.0208357.ref004">4</xref>] Earlier, we showed that minocycline blocks the damage to the white matter and improves cognition in spontaneously hypertensive stroke-prone rats (SHRSPs), which is an animal model of VCID.[<xref ref-type="bibr" rid="pone.0208357.ref005">5</xref>, <xref ref-type="bibr" rid="pone.0208357.ref006">6</xref>] Blood-brain barrier (BBB) disruption mediated by pro-inflammatory matrix metalloproteinases (MMPs) is a major factor in the mechanism of white matter injury.[<xref ref-type="bibr" rid="pone.0208357.ref007">7</xref>, <xref ref-type="bibr" rid="pone.0208357.ref008">8</xref>] Previously, we have shown that SHRSPs subjected to unilateral carotid artery occlusion (UCAO) and Japanese permissive diet (JPD), underwent white matter injury that is associated with BBB disruption.[<xref ref-type="bibr" rid="pone.0208357.ref009">9</xref>] This BBB disruption occurred secondary to increased hypoxia-inducible factor-1α (HIF-1α), a transcriptional regulator elevated during hypoxia, which induced an MMP-9-mediated infiltration of leukocytes.[<xref ref-type="bibr" rid="pone.0208357.ref007">7</xref>] The observed improvements in brain structure and function with minocycline could have been due to an indirect reduction in inflammation by blocking microglia activity or by directly blocking the action of MMP-9.</p>
<p>To resolve this controversy, we studied the impact of two MMP-9 inhibitors in the same animal model that was used to study minocycline. Both inhibitors, DP-460 and SB-3CT, cross the BBB and have been shown to exert beneficial effects in neurological diseases, including acute stroke and amyotrophic lateral sclerosis, but have not been tested in a model of VCID.[<xref ref-type="bibr" rid="pone.0208357.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0208357.ref011">11</xref>] We used SHRSP fed a high salt, low protein JPD to test the effect of the two drugs on white matter injury with MRI and behavior with the Morris Water Maze (MWM).[<xref ref-type="bibr" rid="pone.0208357.ref012">12</xref>, <xref ref-type="bibr" rid="pone.0208357.ref013">13</xref>] We hypothesized that MMP-9 inhibition was the reason for the beneficial effects of minocycline. To test the hypothesis, we obtained two MMP inhibitors, DP-460, an active-site zinc ion chelator, and SB-3CT, a slow-binding inhibitor of MMP-9 that undergoes a reaction within the active site to manifest tight-binding behavior.[<xref ref-type="bibr" rid="pone.0208357.ref014">14</xref>]</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec003">
<title>Animals</title>
<p>All animal studies were reviewed and approved by the Institutional Committee on Animal Use and Care (15-200248-HSC) at the University of New Mexico in accordance with institutional guidelines. Male SHRSP rats were purchased from Charles River Laboratories. Methods for the UCAO surgery, JPD and blood pressure measurements have been reported.[<xref ref-type="bibr" rid="pone.0208357.ref009">9</xref>] Briefly, SHRSPs were purchased at 6 weeks of age. The high salt, low protein diet was administered and UCAO surgery performed at 12 weeks of age. In the UCAO group, the right carotid artery was isolated and double-ligated permanently with 4–0 silk sutures under deep anesthesia with 2.0% isoflurane. Following UCAO, rats were placed on the JPD (16% protein, 0.75% potassium, 4% sodium; Ziegler Bros, Inc.) with 1% sodium chloride added to the drinking water. At the end of the study, animals were deeply anesthetized with sodium pentobarbital and transcardially perfused with ice cold PBS. Brains were removed, separated into right and left hemispheres and snap frozen, then stored at –80°C for later analysis.</p>
</sec>
<sec id="sec004">
<title>DP-460</title>
<p>Twenty SHRSP/JPD/UCAO rats were treated with DP-460 (Produced and tested by D-Pharma in Tel Aviv, Israel) beginning at 12 weeks of life, immediately after the UCAO surgery. Rats were placed on the JPD at the 12 week timepoint.</p>
<p>The DP-460 drug was dissolved in 5% dextrose and injected subcutaneously (every 3<sup>rd</sup> day). Another group of 20 SHRSP/JPD/UCAO rats that were similarly prepared and treated with 5% dextrose served as a control group. An additional untreated group was SHRSP rats who were sham operated (n = 5). The SHRSP/JPD/UCAO animals were started on the JPD at the age of 12 weeks, following right unilateral carotid artery occlusion (UCAO) surgery.</p>
<p>Weight and blood pressure measurements were recorded throughout the study. Behavioral testing for learning/memory was performed during the 15<sup>th</sup> week via the MWM. We used MRI modalities (T2, FA, ADC) to measure water content in the white matter and hippocampus prior to sacrifice at 16 weeks (4 weeks of drug treatment), as previously described.[<xref ref-type="bibr" rid="pone.0208357.ref015">15</xref>] These time points were selected based on a prior study of minocycline. Following sacrifice, animals were perfused with ice cold PBS and brain tissue collected. Experiments were done in duplicates, at two different intervals, with n = 10 rats/group to validate our findings.</p>
</sec>
<sec id="sec005">
<title>SB-3CT</title>
<p>Experiments with SB-3CT (Produced and tested by the Mobashery group in the University of Notre Dame, Notre Dame, Indiana) were carried out similarly to those with DP-460, beginning at 12 weeks of life, and immediately after the UCAO surgery. Rats were placed on the JPD at the 12 week timepoint.</p>
<p>The drug was administered intraperitoneally every other day at a dose of 10 mg/kg. The vehicle for SB-3CT consisted of 30% DMSO, 60% PEG-200 (Sigma-Aldrich, cat # 88440), and 10% sterile water. All animals in the study were sacrificed at the 20<sup>th</sup> week timepoint due to preparation with DMSO, a reagent known to prolong lifespan by acting as a neuroprotectant (following 8 weeks of drug treatment).</p>
</sec>
<sec id="sec006">
<title>MMP-9 measurements</title>
<p>Vehicle (n = 10) and experimental (n = 10) rat brains were separated into left and right hemispheres and weighed after removing the olfactory bulb and the cerebellum/spinal cord. The samples were homogenized in modified (lacking EDTA) RIPA (Radio-Immunoprecipitation Assay) Lysis Buffer, in pre-calculated amounts based on weight. Each of the hemispheres was homogenized, then sonicated to lyse any remaining intact cells. The samples were centrifuged and the supernatant was extracted. The samples were run through the BCA protein assay (Thermo Scientific) to determine the total protein content. Levels of MMP-9 in the samples were assessed by gelation zymography, as described in detail elsewhere.[<xref ref-type="bibr" rid="pone.0208357.ref016">16</xref>] Briefly, proteins were separated electrophoretically on 10% polyacrylamide gels, washed twice in Zymogram Renaturation Buffer (Bio-Rad) and incubated for 96 hours at 37°C in Zymogram Development buffer (Bio-Rad). Gels were then rinsed in tap water and stained for 1 hour in Brilliant Blue R staining solution (Sigma Aldrich). Following the stain, the gels were rinsed twice in tap water and in 10% acetic acid and then incubated in fresh 10% acetic acid over two nights at room temperature. Gels were dried between Gel-Air Cellophane Support sheets (Bio-Rad) overnight. Dried gels were scanned on a transparency scanner (Epson V700) using the TWAIN capture feature of Photoshop (Adobe Inc.) and lytic bands were measured densitometrically with AlphaEase FC (Alpha Innotech).</p>
</sec>
<sec id="sec007">
<title>Statistical analysis</title>
<p>All data was confirmed by a Clinical Translational Science Center biostatistian at the University of New Mexico and all significance tests were performed at the 0.05 level of significance. Pairwise correlations between the measured variables (PT time, PT crosses, HIPP T2, CA1 T2, CC T2, EL time) were estimated and tested using Kendal’s Tau statistic, as all variable pairs exhibited roughly monotonic (but not necessarily linear) associations. MMP-9 measurement data was prepared using Prism (version 6 Graphpad Software Inc.) and expressed as Integrated Density Value of the lysed 92kDa bands on the gels. One-way ANOVA was performed to detect if any differences were present among the means of the 3 groups (treatment, vehicle, and control). T-tests were used for two group comparisons, as appropriate, for weight, blood pressure, MWM and MMP-9 level comparisons of drug and VEH groups.</p>
</sec>
</sec>
<sec id="sec008" sec-type="results">
<title>Results</title>
<p>The effect of the two drugs on blood pressure and weight in comparison to the appropriate controls is shown in <bold><xref ref-type="fig" rid="pone.0208357.g001">Fig 1</xref> </bold>(refer to <bold><xref ref-type="supplementary-material" rid="pone.0208357.s001">S1 Fig</xref></bold> for a detailed table). DP-460 caused a decrease in weight at 15 weeks compared to 13 week and 14 week timepoints (p = 0.004, p = 0.011; <bold><xref ref-type="fig" rid="pone.0208357.g001">Fig 1A</xref></bold>) and an increase in blood pressure at 15 weeks (p = 0.007; <bold><xref ref-type="fig" rid="pone.0208357.g001">Fig 1B</xref>)</bold> compared to the VEH group. SB-3CT increased weight at 14 weeks (p = 0.015; <bold><xref ref-type="fig" rid="pone.0208357.g001">Fig 1C</xref></bold>) and had a variable effect on blood pressure (drug at 13 week (p&lt;0.001), 15 week (p&lt;0.001), 16 week (p = 0.050), 17 week (p = 0.004) and 18 week (p = 0.009) compared to VEH; <bold><xref ref-type="fig" rid="pone.0208357.g001">Fig 1D</xref></bold>).</p>
<fig id="pone.0208357.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0208357.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Distribution of WT and BP data for DP-460 and SB-3CT drug study animals.</title>
<p>(A). Timecourse of WT distribution for SHRSP/JPD/UCAO treated with the DP-460 drug compared with 5% dextrose-treated control rats. Significantly lower WT was detected at 15 weeks in treated rats compared to the 13 week (*p = 0.004) and 14 week (*p = 0.011) VEH group. (B). Timecourse of BP distribution in SHRSP/JPD/UCAO treated with the DP-460 drug compared with 5% dextrose-treated control rats. BP was significantly elevated at 15 weeks in drug versus 11 weeks vehicle group (*p = 0.007). (C). SB-3CT WT distribution over 20 weeks of rat life compared to the VEH group. Higher WT was found at 14 weeks in the SHRSP/JPD/UCAO drug group compared to 18 weeks in the DMSO-treated VEH group (*p = 0.015). (D). A BP timecourse for SB-3CT comparison with DMSO-treated VEH shows several significant findings: drug at 13 week (*p&lt;0.001), 15 week (*p&lt;0.001), 16 week (**p = 0.050), 17 week (***p = 0.004) and 18 week (****p = 0.009) compared to 11 week VEH; VEH at 13 week (^^p = 0.043), 17 week (****p = 0.009), 18 week (^p = 0.002) compared to 11 week VEH. Data is based on drug (n = 20) and VEH (n = 5) groups for DP-460 and SB-3CT studies, respectively. The black arrow at the 12 week timepoint per graph represent the beginning of the JPD. Week (W).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0208357.g001" xlink:type="simple"/>
</fig>
<p>MRI measurements of T2, diffusion as measured with fractional anisotropy (FA), apparent diffusion coefficient (ADC) in the gray (hippocampus) and white matter (corpus callosum, external capsule) regions are shown in <bold><xref ref-type="table" rid="pone.0208357.t001">Table 1</xref></bold>. Neither DP-460 nor SB-3CT had a significant effect on any of the MRI variables.</p>
<table-wrap id="pone.0208357.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0208357.t001</object-id>
<label>Table 1</label> <caption><title>MRI modalities are unchanged between treatment and control groups for DP-460 and SB-3CT studies.</title></caption>
<alternatives>
<graphic id="pone.0208357.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0208357.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="center" colspan="3">Corpus Callosum</th>
<th align="center" colspan="3">External Capsule</th>
<th align="center" colspan="3">Hippocampus</th>
</tr>
<tr>
<th align="left"/>
<th align="center">T2-MRI</th>
<th align="center">FA</th>
<th align="center">ADC</th>
<th align="center">T2-MRI</th>
<th align="center">FA</th>
<th align="center">ADC</th>
<th align="center">T2-MRI</th>
<th align="center">FA</th>
<th align="center">ADC</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">DP-460</td>
<td align="center">2.80±0.12</td>
<td align="center">0.26±0.01</td>
<td align="center">0.00083± 0.0000078</td>
<td align="center">2.53±0.12</td>
<td align="center">0.25±0.02</td>
<td align="center">0.00085±0.000019</td>
<td align="center">2.75±0.17</td>
<td align="center">0.39±0.01</td>
<td align="center">0.0009± 0.000012</td>
</tr>
<tr>
<td align="center">DP-460 VEH</td>
<td align="center">2.90±0.15</td>
<td align="center">0.27±0.01</td>
<td align="center">0.00082± 0.000007</td>
<td align="center">2.72±0.13</td>
<td align="center">0.25±0.02</td>
<td align="center">0.00083±0.000014</td>
<td align="center">2.50±0.19</td>
<td align="center">0.41±0.01</td>
<td align="center">0.00089±0.000018</td>
</tr>
<tr>
<td align="center">DP-460 CONT</td>
<td align="center">2.38±0.06</td>
<td align="center">0.26±0.01</td>
<td align="center">0.00082± 0.000014</td>
<td align="center">2.38±0.03</td>
<td align="center">0.24±0.03</td>
<td align="center">0.00081±0.000013</td>
<td align="center">2.45±0.13</td>
<td align="center">0.40±0.02</td>
<td align="center">0.00089±0.000015</td>
</tr>
<tr>
<td align="center">SB-3CT</td>
<td align="center">2.75±0.19</td>
<td align="center">0.31±0.03</td>
<td align="center"/>
<td align="center">2.70±0.21</td>
<td align="center"/>
<td align="center"/>
<td align="center">2.73±0.30</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">SB-3CT VEH</td>
<td align="center">2.85±0.21</td>
<td align="center">0.25±0.02</td>
<td align="center"/>
<td align="center">2.89±0.23</td>
<td align="center"/>
<td align="center"/>
<td align="center">2.62±0.16</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">SB-3CT CONT</td>
<td align="left">3.84±0.96</td>
<td align="center">0.31±0.03</td>
<td align="center"/>
<td align="center"><break/>3.08±0.39</td>
<td align="center"/>
<td align="center"/>
<td align="center">2.90±0.23</td>
<td align="center"/>
<td align="center"/>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>Structural brain imaging of normalized T2-MRI intensity ratios and diffusion tensor imaging parameters (FA, ADC) are not significantly different between DP-460-treated, VEH-treated and untreated, naïve control groups. Data analyses of T2-MRI and FA imaging parameters failed to show significant differences between SB-3CT-treated, VEH-treated and naïve control groups. Data is represented as mean±SE and analyzed using a one-Way ANOVA. None of the p-values associated with the one-way ANOVA tests were found to be significant at the 0.05 level.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Representative T2-MRI images of DP-460 and SB-3CT brains are shown in <bold><xref ref-type="fig" rid="pone.0208357.g002">Fig 2</xref></bold>. No visible changes were observed among brains from the DP-460, SB-3CT and naïve control groups.</p>
<fig id="pone.0208357.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0208357.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Brains are unchanged with DP-460 and SB-3CT treatments.</title>
<p>Representative T2-MRI images were obtained at 16 weeks of life for DP-460 and 20 weeks of life for SB-3CT. No differences were found among treatment and control groups (n = 10/group).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0208357.g002" xlink:type="simple"/>
</fig>
<p>Unexpectedly, behavioral studies in the MWM studies showed an impaired ability to learn with DP-460 and no effect on learning with SB-3CT. The time spent (<bold><xref ref-type="fig" rid="pone.0208357.g003">Fig 3A</xref></bold>) and number of crosses (<bold><xref ref-type="fig" rid="pone.0208357.g003">Fig 3B</xref></bold>) in the Southwest quadrant was significantly less with DP-460 treatment, indicating that the drug impaired performance. Treatment with SB-3CT had no effect on learning, likely due to its distinct mechanism of action compared to DP-460. Refer to <bold><xref ref-type="supplementary-material" rid="pone.0208357.s002">S2 Fig</xref></bold> for a detailed table.</p>
<fig id="pone.0208357.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0208357.g003</object-id>
<label>Fig 3</label>
<caption>
<title>DP-460 impairs learning and memory in the Morris water maze.</title>
<p>A significant decrease in time spent in seconds for the DP-460 group (A) and the number of crosses (B) in the Southwest (SW) quadrant during the probe trial (*p&lt;0.001), indicates poorer performance for the drug-treated animals. Corresponding trace diagrams reveal the swimming path of the rat to the goal quadrant.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0208357.g003" xlink:type="simple"/>
</fig>
<p>For the DP-460 study, a modest positive association was found between the time spent in the probe trial of the MWM and hippocampus CA1 hyperintensities (Kendall’s Tau: 0.31, p = 0.02), while a modest negative association was found between the number of crosses of the goal platform in the probe trial and corpus callosum hyperintensities (Kendall’s Tau: -0.37, p&lt;0.01). For the SB-3CT study, a moderate positive association was found between total hippocampus hyperintensities and escape latency, the time it takes to find the goal platform in the MWM (Kendall’s Tau: 0.47, p = 0.03; <bold><xref ref-type="table" rid="pone.0208357.t002">Table 2</xref></bold>).</p>
<table-wrap id="pone.0208357.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0208357.t002</object-id>
<label>Table 2</label> <caption><title>Significant Kendall’s Tau correlations for DP-460 and SB-3CT drug studies.</title></caption>
<alternatives>
<graphic id="pone.0208357.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0208357.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Drug Study</th>
<th align="center">Variable 1</th>
<th align="center">Variable 2</th>
<th align="center">Kendall’s Tau</th>
<th align="center">p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" style="background-color:#CCCCCC"><bold>DP-460</bold></td>
<td align="center" style="background-color:#CCCCCC">PT Time</td>
<td align="center" style="background-color:#CCCCCC">CA1 T2</td>
<td align="center" style="background-color:#CCCCCC">0.31</td>
<td align="center" style="background-color:#CCCCCC">0.02</td>
</tr>
<tr>
<td align="center"><bold>DP-460</bold></td>
<td align="center">PT Crosses</td>
<td align="center">CC T2</td>
<td align="center">-0.37</td>
<td align="center">&lt;0.01</td>
</tr>
<tr>
<td align="center" style="background-color:#CCCCCC"><bold>SB-3CT</bold></td>
<td align="center" style="background-color:#CCCCCC">HIPP T2</td>
<td align="center" style="background-color:#CCCCCC">EL Time</td>
<td align="center" style="background-color:#CCCCCC">0.47</td>
<td align="center" style="background-color:#CCCCCC">0.03</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>Calculations of Kendall’s Tau detected several significant correlations between two measured variables in the drug studies. CA1-cornu Ammon (a hippocampal subregion); CC-corpus callosum; EL-escape latency; HIPP-hippocampus; MWM-Morris Water Maze; PT-probe trial; T2-T2-weighted imaging (transverse relaxation time in MRI).</p></fn>
</table-wrap-foot>
</table-wrap>
<p>We used gel zymography to determine the level of MMP-9 in the tissues of the animals treated with DP-460, which showed the negative impact on learning. The levels of MMP-9 detected in the post-treatment tissues were unchanged by the drug (p = 0.067, <bold><xref ref-type="fig" rid="pone.0208357.g004">Fig 4</xref></bold>; refer to <bold><xref ref-type="supplementary-material" rid="pone.0208357.s003">S3 Fig</xref></bold> for a detailed table). Since SB-3CT failed to affect either the MRI variables or the behavior, measurements of MMPs in the tissue were not obtained.</p>
<fig id="pone.0208357.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0208357.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Gel zymography for MMP-9 levels.</title>
<p>No significant differences were observed for MMP-9 levels between DP-460 drug and VEH groups. MMP-9 levels were expressed as integrated density value of 92kDa lytic bands on zymographic gels. Data is represented as box plots, with the median and interquartile ranges (n = 10 rats per group).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0208357.g004" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec009" sec-type="conclusions">
<title>Discussion</title>
<p>A number of studies have shown that MMPs have a detrimental effect in neurological diseases and that MMP inhibitors can help reduce the injury.[<xref ref-type="bibr" rid="pone.0208357.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0208357.ref017">17</xref>, <xref ref-type="bibr" rid="pone.0208357.ref018">18</xref>] During an acute stroke, there is disruption of the BBB with breakdown of extracellular matrix and tight junction proteins by MMPs, particularly MMP-9.[<xref ref-type="bibr" rid="pone.0208357.ref008">8</xref>] In an animal model of chronic stroke with features similar to patients with VCID, treatment with two relatively selective MMP-9 inhibitors failed to show improvement in MRI parameters and behavioral measures. DP-460 had a detrimental effect on learning, while SB-3CT had no effect. This unexpected result suggests that minocycline’s beneficial action in our previous studies was not related to inhibition of MMP-9, but rather to a broader, pleiotropic effect on inflammation that could involve suppression of microglia and multiple MMPs.[<xref ref-type="bibr" rid="pone.0208357.ref019">19</xref>–<xref ref-type="bibr" rid="pone.0208357.ref022">22</xref>] The lack of benefit by both MMP-9 inhibitors, DP-460 and SB-3CT, which cross the blood-brain barrier, suggests that MMP-9 is not the major factor driving the white matter damage in the SHRSP model of vascular cognitive impairment.[<xref ref-type="bibr" rid="pone.0208357.ref023">23</xref>]</p>
<p>There are several explanations for the lack of an effect of either agent on the white matter damage measured with MRI and behavior measured by the MWM. It is possible that MMP-9 is not the major MMP involved in chronic ischemia as opposed to acute cerebral ischemia, where it is a major factor. Other MMPs are expressed in the brain cells of the SHRSP model. Stromelysin-1 (MMP-3) is produced by microglia, pericytes, and macrophages. Astrocytes produce MMP-2. Neurons have MMP-10.[<xref ref-type="bibr" rid="pone.0208357.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0208357.ref025">25</xref>] SB-3CT is a slow-binding inhibitor for MMP-2 and MMP-8 and linear-competitive inhibitor of MMP-14. It is very potent for MMP-2 and MMP-9.[<xref ref-type="bibr" rid="pone.0208357.ref014">14</xref>] The profile for DP-460 MMP inhibition may be broader than the SB-3CT compound. Thus, other MMPs may be more important contributors to brain damage than MMP-9 alone.</p>
<p>The two agents have different mechanisms of action: DP-460 chelates the active-site zinc ion of the MMP within the catalytic domain,[<xref ref-type="bibr" rid="pone.0208357.ref026">26</xref>] while SB-3CT binds the active site and uses the catalytic machinery of the enzyme to undergo a reaction that generates a species, resulting in tight-binding inhibition. In light of the fact that this reaction has been documented only within the active-site of gelatinase (MMP-2 and MMP-9), the compound affords high selectivity for targeting of these enzymes.[<xref ref-type="bibr" rid="pone.0208357.ref014">14</xref>] The impairment of learning induced by DP-460 suggests that it had a central action, albeit a detrimental one, possibly due to its lack of high selectivity for MMP-9.</p>
<p>While this study was underway, several reports appeared that could shed light on the negative effects of MMP-9 inhibition in chronic stroke. Other investigators found that MMP-9 inhibitors blocked the formation of perineuronal nets involved in formation of synapses.[<xref ref-type="bibr" rid="pone.0208357.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0208357.ref028">28</xref>] These synaptic nets are critical for consolidation of learning. Thus, a probable explanation of the negative effect of DP-460 on learning in the MWM is that MMP-9 is necessary for memory consolidation and the DP-460 drug lacked high selectivity for this MMP isoform. MMP-9 is necessary for synaptic remodeling, most likely through its action on perineuronal nets.[<xref ref-type="bibr" rid="pone.0208357.ref027">27</xref>–<xref ref-type="bibr" rid="pone.0208357.ref029">29</xref>] In those studies, the investigators found impaired learning in the MWM in rats treated with an MMP-9 inhibitor, DP-b99, which provides the most plausible explanation of the impaired learning seen in our study.[<xref ref-type="bibr" rid="pone.0208357.ref030">30</xref>]</p>
<p>In studies of humans with VCID, we and others have shown elevation of several MMPs in CSF.[<xref ref-type="bibr" rid="pone.0208357.ref031">31</xref>, <xref ref-type="bibr" rid="pone.0208357.ref032">32</xref>] MMP-2 is reduced and MMP-9 elevated in the CSF of patients with VCID. MMP-10 is increased in CSF of patients with Alzheimer’s disease and MMP-3 is elevated in mixed dementia (unpublished data).</p>
<p>There is increasing evidence that MMP-9 is important in the formation of synapses after an injury.[<xref ref-type="bibr" rid="pone.0208357.ref033">33</xref>] This has been demonstrated by several groups of investigators, who have shown that blocking MMP-9 reduces synaptic plasticity and hinders learning and memory. Neuronal MMP-9 has been implicated in synaptic plasticity through the regulation of dendritic spine structure and excitatory synapse function.[<xref ref-type="bibr" rid="pone.0208357.ref034">34</xref>, <xref ref-type="bibr" rid="pone.0208357.ref035">35</xref>] Additional evidence suggests that inhibition of MMP-9 could block hippocampal neurogenesis.[<xref ref-type="bibr" rid="pone.0208357.ref036">36</xref>]</p>
<p>Our results show that drugs that affect acute ischemic injury may not be suitable for chronic ischemia, and that while MMPs have a detrimental effect in the early stages of an injury, they are important in the later recovery phases. Furthermore, these results suggest that the anti-inflammatory effects of minocycline, which was beneficial in reducing white matter injury and cognitive deficits in the same animal model, must be acting through other mechanisms than direct inhibition of MMP-9. More research will be needed to characterize the sequence of MMP expression over time and the production of other factors that could contribute to the white matter injury. A general finding with the MMP inhibitors is that they have both beneficial and detrimental actions, depending on the timing of their use after the injury.[<xref ref-type="bibr" rid="pone.0208357.ref037">37</xref>, <xref ref-type="bibr" rid="pone.0208357.ref038">38</xref>] Since minocycline showed greater efficacy, the role of inflammation appears to be critical, and the design and testing of agents that act on the MMPs at the earlier inflammatory stage, without interfering with the recovery process, are now needed.</p>
</sec>
<sec id="sec010">
<title>Supporting information</title>
<supplementary-material id="pone.0208357.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0208357.s001" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Distribution of WT and BP data for DP-460 and SB-3CT drug study animals.</title>
<p>Timecourse of data distribution for WT and BP for the DP-460 and SB-3CT drugs are presented as mean±SE.</p>
<p>(TIFF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0208357.s002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0208357.s002" xlink:type="simple">
<label>S2 Fig</label>
<caption>
<title>DP-460 impairs learning and memory in the Morris water maze.</title>
<p>Data distribution for the probe trial duration of time spent in the SW quadrant (n = 20 rats/group) and the number of crosses in the SW quadrant (n = 10 rats/group) are presented for the DP-460 drug study.</p>
<p>(TIFF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0208357.s003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0208357.s003" xlink:type="simple">
<label>S3 Fig</label>
<caption>
<title>Gel zymography for MMP-9 levels.</title>
<p>Data distribution for DP-460 drug study MMP-9 levels as compared to the VEH group. Note that some data values were below the detection threshold of assay, and therefore omitted.</p>
<p>(TIFF)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>The authors would like to thank Carolyn Nighbert, the student in the lab, for her technical help with experiments. We also thank Yirong Yang, PhD, for acquiring the MRI of our rats. Finally, we are grateful to Fakhreya Jalal, PhD, for establishing the high salt rat model in the lab, on which this research project is based.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0208357.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gorelick</surname> <given-names>PB</given-names></name>, <name name-style="western"><surname>Scuteri</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Black</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Decarli</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Greenberg</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Iadecola</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association</article-title>. <source>Stroke</source>. <year>2011</year>;<volume>42</volume>(<issue>9</issue>):<fpage>2672</fpage>–<lpage>713</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STR.0b013e3182299496" xlink:type="simple">10.1161/STR.0b013e3182299496</ext-link></comment> <object-id pub-id-type="pmid">21778438</object-id>; PubMed Central PMCID: PMC3778669.</mixed-citation></ref>
<ref id="pone.0208357.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Snyder</surname> <given-names>HM</given-names></name>, <name name-style="western"><surname>Corriveau</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Craft</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Faber</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Greenberg</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Knopman</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Vascular contributions to cognitive impairment and dementia including Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2015</year>;<volume>11</volume>(<issue>6</issue>):<fpage>710</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jalz.2014.10.008" xlink:type="simple">10.1016/j.jalz.2014.10.008</ext-link></comment> <object-id pub-id-type="pmid">25510382</object-id>; PubMed Central PMCID: PMC4731036.</mixed-citation></ref>
<ref id="pone.0208357.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Iadecola</surname> <given-names>C</given-names></name>. <article-title>The pathobiology of vascular dementia</article-title>. <source>Neuron</source>. <year>2013</year>;<volume>80</volume>(<issue>4</issue>):<fpage>844</fpage>–<lpage>66</lpage>. Epub 2013/11/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.neuron.2013.10.008" xlink:type="simple">10.1016/j.neuron.2013.10.008</ext-link></comment> <object-id pub-id-type="pmid">24267647</object-id>; PubMed Central PMCID: PMC3842016.</mixed-citation></ref>
<ref id="pone.0208357.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rosenberg</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Wallin</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Wardlaw</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Markus</surname> <given-names>HS</given-names></name>, <name name-style="western"><surname>Montaner</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wolfson</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Consensus statement for diagnosis of subcortical small vessel disease</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>2016</year>;<volume>36</volume>(<issue>1</issue>):<fpage>6</fpage>–<lpage>25</lpage>. Epub 2015/07/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/jcbfm.2015.172" xlink:type="simple">10.1038/jcbfm.2015.172</ext-link></comment> <object-id pub-id-type="pmid">26198175</object-id>; PubMed Central PMCID: PMC4758552.</mixed-citation></ref>
<ref id="pone.0208357.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Madigan</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Wilcock</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Hainsworth</surname> <given-names>AH</given-names></name>. <article-title>Vascular Contributions to Cognitive Impairment and Dementia: Topical Review of Animal Models</article-title>. <source>Stroke</source>. <year>2016</year>;<volume>47</volume>(<issue>7</issue>):<fpage>1953</fpage>–<lpage>9</lpage>. Epub 2016/06/16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.116.012066" xlink:type="simple">10.1161/STROKEAHA.116.012066</ext-link></comment> <object-id pub-id-type="pmid">27301939</object-id>; PubMed Central PMCID: PMCPMC4927375.</mixed-citation></ref>
<ref id="pone.0208357.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Kimura-Ohba</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Rosenberg</surname> <given-names>GA</given-names></name>. <article-title>Rodent Models of Vascular Cognitive Impairment</article-title>. <source>Transl Stroke Res</source>. <year>2016</year>;<volume>7</volume>(<issue>5</issue>):<fpage>407</fpage>–<lpage>14</lpage>. Epub 2016/08/09. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s12975-016-0486-2" xlink:type="simple">10.1007/s12975-016-0486-2</ext-link></comment> <object-id pub-id-type="pmid">27498679</object-id>; PubMed Central PMCID: PMCPMC5016244.</mixed-citation></ref>
<ref id="pone.0208357.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jalal</surname> <given-names>FY</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Roitbak</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Rosenberg</surname> <given-names>GA</given-names></name>. <article-title>Hypoxia-induced neuroinflammatory white-matter injury reduced by minocycline in SHR/SP</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>2015</year>;<volume>35</volume>(<issue>7</issue>):<fpage>1145</fpage>–<lpage>53</lpage>. Epub 2015/02/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/jcbfm.2015.21" xlink:type="simple">10.1038/jcbfm.2015.21</ext-link></comment> <object-id pub-id-type="pmid">25712499</object-id>.</mixed-citation></ref>
<ref id="pone.0208357.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Kimura-Ohba</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Salayandia</surname> <given-names>VM</given-names></name>, <name name-style="western"><surname>Cosse</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Raz</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Vascular tight junction disruption and angiogenesis in spontaneously hypertensive rat with neuroinflammatory white matter injury</article-title>. <source>Neurobiology of disease</source>. <year>2018</year>;<volume>114</volume>:<fpage>95</fpage>–<lpage>110</lpage>. Epub 2018/02/28. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.nbd.2018.02.012" xlink:type="simple">10.1016/j.nbd.2018.02.012</ext-link></comment> <object-id pub-id-type="pmid">29486300</object-id>; PubMed Central PMCID: PMCPMC5891378.</mixed-citation></ref>
<ref id="pone.0208357.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jalal</surname> <given-names>FY</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lopez</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Rosenberg</surname> <given-names>GA</given-names></name>. <article-title>Myelin loss associated with neuroinflammation in hypertensive rats</article-title>. <source>Stroke</source>. <year>2012</year>;<volume>43</volume>(<issue>4</issue>):<fpage>1115</fpage>–<lpage>22</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.111.643080" xlink:type="simple">10.1161/STROKEAHA.111.643080</ext-link></comment> <object-id pub-id-type="pmid">22363061</object-id>; PubMed Central PMCID: PMC3598597.</mixed-citation></ref>
<ref id="pone.0208357.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gu</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Cui</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Brown</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Fridman</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Mobashery</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Strongin</surname> <given-names>AY</given-names></name>, <etal>et al</etal>. <article-title>A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia</article-title>. <source>J Neurosci</source>. <year>2005</year>;<volume>25</volume>(<issue>27</issue>):<fpage>6401</fpage>–<lpage>8</lpage>. Epub 2005/07/08. doi: 25/27/6401 [pii] <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1523/JNEUROSCI.1563-05.2005" xlink:type="simple">10.1523/JNEUROSCI.1563-05.2005</ext-link></comment> <object-id pub-id-type="pmid">16000631</object-id>.</mixed-citation></ref>
<ref id="pone.0208357.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Petri</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Calingasan</surname> <given-names>NY</given-names></name>, <name name-style="western"><surname>Alsaied</surname> <given-names>OA</given-names></name>, <name name-style="western"><surname>Wille</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Kiaei</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Friedman</surname> <given-names>JE</given-names></name>, <etal>et al</etal>. <article-title>The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis</article-title>. <source>Journal of neurochemistry</source>. <year>2007</year>;<volume>102</volume>(<issue>3</issue>):<fpage>991</fpage>–<lpage>1000</lpage>. Epub 2007/07/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1471-4159.2007.04604.x" xlink:type="simple">10.1111/j.1471-4159.2007.04604.x</ext-link></comment> <object-id pub-id-type="pmid">17630988</object-id>.</mixed-citation></ref>
<ref id="pone.0208357.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kitamura</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Fujita</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Oishi</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Kalaria</surname> <given-names>RN</given-names></name>, <name name-style="western"><surname>Washida</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Maki</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Selective white matter abnormalities in a novel rat model of vascular dementia</article-title>. <source>Neurobiology of aging</source>. <year>2012</year>;<volume>33</volume>(<issue>5</issue>):<fpage>1012</fpage> e25-35. Epub 2011/12/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.neurobiolaging.2011.10.033" xlink:type="simple">10.1016/j.neurobiolaging.2011.10.033</ext-link></comment> <object-id pub-id-type="pmid">22133276</object-id>.</mixed-citation></ref>
<ref id="pone.0208357.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sironi</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Guerrini</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Tremoli</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Miller</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Gelosa</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Lascialfari</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Analysis of pathological events at the onset of brain damage in stroke-prone rats: a proteomics and magnetic resonance imaging approach</article-title>. <source>J Neurosci Res</source>. <year>2004</year>;<volume>78</volume>(<issue>1</issue>):<fpage>115</fpage>–<lpage>22</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/jnr.20219" xlink:type="simple">10.1002/jnr.20219</ext-link></comment> <object-id pub-id-type="pmid">15372505</object-id>.</mixed-citation></ref>
<ref id="pone.0208357.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Forbes</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Shi</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Fisher</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hesek</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Llarrull</surname> <given-names>LI</given-names></name>, <etal>et al</etal>. <article-title>Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases</article-title>. <source>Chem Biol Drug Des</source>. <year>2009</year>;<volume>74</volume>(<issue>6</issue>):<fpage>527</fpage>–<lpage>34</lpage>. Epub 2009/10/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1747-0285.2009.00881.x" xlink:type="simple">10.1111/j.1747-0285.2009.00881.x</ext-link></comment> <object-id pub-id-type="pmid">19807733</object-id>; PubMed Central PMCID: PMCPMC2837476.</mixed-citation></ref>
<ref id="pone.0208357.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sood</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Taheri</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Estrada</surname> <given-names>EY</given-names></name>, <name name-style="western"><surname>Rosenberg</surname> <given-names>GA</given-names></name>. <article-title>Quantitative evaluation of the effect of propylene glycol on BBB permeability</article-title>. <source>J Magn Reson Imaging</source>. <year>2007</year>;<volume>25</volume>(<issue>1</issue>):<fpage>39</fpage>–<lpage>47</lpage>. Epub 2006/12/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/jmri.20802" xlink:type="simple">10.1002/jmri.20802</ext-link></comment> <object-id pub-id-type="pmid">17173307</object-id>.</mixed-citation></ref>
<ref id="pone.0208357.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rosenberg</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Dencoff</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>McGuire</surname> <given-names>PG</given-names></name>, <name name-style="western"><surname>Liotta</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Stetler-Stevenson</surname> <given-names>WG</given-names></name>. <article-title>Injury-induced 92-kDa gelatinase and urokinase expression in rat brain</article-title>. <source>LabInvest</source>. <year>1994</year>;<volume>71</volume>(<issue>3</issue>):<fpage>417</fpage>–<lpage>22</lpage>.</mixed-citation></ref>
<ref id="pone.0208357.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rosenberg</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Navratil</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Barone</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Feuerstein</surname> <given-names>G</given-names></name>. <article-title>Proteolytic cascade enzymes increase in focal cerebral ischemia in rat</article-title>. <source>Journal of Cerebral Blood Flow &amp; Metabolism</source>. <year>1996</year>;<volume>16</volume>(<issue>3</issue>):<fpage>360</fpage>–<lpage>6</lpage>.</mixed-citation></ref>
<ref id="pone.0208357.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhao</surname> <given-names>BQ</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>HY</given-names></name>, <name name-style="western"><surname>Storrie</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Rosen</surname> <given-names>BR</given-names></name>, <name name-style="western"><surname>Mooney</surname> <given-names>DJ</given-names></name>, <etal>et al</etal>. <article-title>Role of matrix metalloproteinases in delayed cortical responses after stroke</article-title>. <source>NatMed</source>. <year>2006</year>;<volume>12</volume>(<issue>4</issue>):<fpage>441</fpage>–<lpage>5</lpage>.</mixed-citation></ref>
<ref id="pone.0208357.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jin</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>KJ</given-names></name>, <name name-style="western"><surname>Rosenberg</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>W</given-names></name>. <article-title>Normobaric hyperoxia combined with minocycline provides greater neuroprotection than either alone in transient focal cerebral ischemia</article-title>. <source>Experimental neurology</source>. <year>2013</year>;<volume>240</volume>:<fpage>9</fpage>–<lpage>16</lpage>. Epub 2012/12/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.expneurol.2012.11.018" xlink:type="simple">10.1016/j.expneurol.2012.11.018</ext-link></comment> <object-id pub-id-type="pmid">23195595</object-id>; PubMed Central PMCID: PMC3563388.</mixed-citation></ref>
<ref id="pone.0208357.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Giuliani</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Hader</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Yong</surname> <given-names>VW</given-names></name>. <article-title>Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction</article-title>. <source>J LeukocBiol</source>. <year>2005</year>;<volume>78</volume>(<issue>1</issue>):<fpage>135</fpage>–<lpage>43</lpage>.</mixed-citation></ref>
<ref id="pone.0208357.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Machado</surname> <given-names>LS</given-names></name>, <name name-style="western"><surname>Kozak</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ergul</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hess</surname> <given-names>DC</given-names></name>, <name name-style="western"><surname>Borlongan</surname> <given-names>CV</given-names></name>, <name name-style="western"><surname>Fagan</surname> <given-names>SC</given-names></name>. <article-title>Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke</article-title>. <source>BMC neuroscience</source>. <year>2006</year>;<volume>7</volume>:<fpage>56</fpage>. Epub 2006/07/19. doi: 1471-2202-7-56 [pii] <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2202-7-56" xlink:type="simple">10.1186/1471-2202-7-56</ext-link></comment> <object-id pub-id-type="pmid">16846501</object-id>; PubMed Central PMCID: PMC1543649.</mixed-citation></ref>
<ref id="pone.0208357.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Power</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Henry</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Del Bigio</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>Larsen</surname> <given-names>PH</given-names></name>, <name name-style="western"><surname>Corbett</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Imai</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases</article-title>. <source>AnnNeurol</source>. <year>2003</year>;<volume>53</volume>(<issue>6</issue>):<fpage>731</fpage>–<lpage>42</lpage>.</mixed-citation></ref>
<ref id="pone.0208357.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gooyit</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Suckow</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Schroeder</surname> <given-names>VA</given-names></name>, <name name-style="western"><surname>Wolter</surname> <given-names>WR</given-names></name>, <name name-style="western"><surname>Mobashery</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>M</given-names></name>. <article-title>Selective gelatinase inhibitor neuroprotective agents cross the blood-brain barrier</article-title>. <source>ACS Chem Neurosci</source>. <year>2012</year>;<volume>3</volume>(<issue>10</issue>):<fpage>730</fpage>–<lpage>6</lpage>. Epub 2012/10/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1021/cn300062w" xlink:type="simple">10.1021/cn300062w</ext-link></comment> <object-id pub-id-type="pmid">23077716</object-id>; PubMed Central PMCID: PMCPMC3474282.</mixed-citation></ref>
<ref id="pone.0208357.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rosenberg</surname> <given-names>GA</given-names></name>. <article-title>Matrix Metalloproteinase-Mediated Neuroinflammation in Vascular Cognitive Impairment of the Binswanger Type</article-title>. <source>Cell Mol Neurobiol</source>. <year>2016</year>;<volume>36</volume>(<issue>2</issue>):<fpage>195</fpage>–<lpage>202</lpage>. Epub 2016/03/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10571-015-0277-4" xlink:type="simple">10.1007/s10571-015-0277-4</ext-link></comment> <object-id pub-id-type="pmid">26993507</object-id>; PubMed Central PMCID: PMCPMC4861651.</mixed-citation></ref>
<ref id="pone.0208357.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cuadrado</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Rosell</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Penalba</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Slevin</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Alvarez-Sabin</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ortega-Aznar</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study</article-title>. <source>J Proteome Res</source>. <year>2009</year>;<volume>8</volume>(<issue>6</issue>):<fpage>3191</fpage>–<lpage>7</lpage>. Epub 2009/03/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1021/pr801012x" xlink:type="simple">10.1021/pr801012x</ext-link></comment> <object-id pub-id-type="pmid">19317417</object-id>.</mixed-citation></ref>
<ref id="pone.0208357.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Diener</surname> <given-names>HC</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Lampl</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Bornstein</surname> <given-names>NM</given-names></name>, <name name-style="western"><surname>Kozak</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rosenberg</surname> <given-names>G</given-names></name>. <article-title>DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke</article-title>. <source>Stroke</source>. <year>2008</year>;<volume>39</volume>(<issue>6</issue>):<fpage>1774</fpage>–<lpage>8</lpage>. Epub 2008/04/12. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.107.506378" xlink:type="simple">10.1161/STROKEAHA.107.506378</ext-link></comment> <object-id pub-id-type="pmid">18403736</object-id>.</mixed-citation></ref>
<ref id="pone.0208357.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tsilibary</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Tzinia</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Radenovic</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Stamenkovic</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Lebitko</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Mucha</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Neural ECM proteases in learning and synaptic plasticity</article-title>. <source>Prog Brain Res</source>. <year>2014</year>;<volume>214</volume>:<fpage>135</fpage>–<lpage>57</lpage>. Epub 2014/11/21. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/B978-0-444-63486-3.00006-2" xlink:type="simple">10.1016/B978-0-444-63486-3.00006-2</ext-link></comment> <object-id pub-id-type="pmid">25410356</object-id>.</mixed-citation></ref>
<ref id="pone.0208357.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kwok</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Dick</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Fawcett</surname> <given-names>JW</given-names></name>. <article-title>Extracellular matrix and perineuronal nets in CNS repair</article-title>. <source>Developmental neurobiology</source>. <year>2011</year>;<volume>71</volume>(<issue>11</issue>):<fpage>1073</fpage>–<lpage>89</lpage>. Epub 2011/09/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/dneu.20974" xlink:type="simple">10.1002/dneu.20974</ext-link></comment> <object-id pub-id-type="pmid">21898855</object-id>.</mixed-citation></ref>
<ref id="pone.0208357.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yeghiazaryan</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Rutkowska-Wlodarczyk</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Konopka</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Wilczynski</surname> <given-names>GM</given-names></name>, <name name-style="western"><surname>Melikyan</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Korkotian</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>6</issue>):<fpage>e99789</fpage>. Epub 2014/06/12. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0099789" xlink:type="simple">10.1371/journal.pone.0099789</ext-link></comment> <object-id pub-id-type="pmid">24918931</object-id>; PubMed Central PMCID: PMC4053404.</mixed-citation></ref>
<ref id="pone.0208357.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vafadari</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Salamian</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kaczmarek</surname> <given-names>L</given-names></name>. <article-title>MMP-9 in Translation: From Molecule to Brain Physiology, Pathology and Therapy</article-title>. <source>Journal of neurochemistry</source>. <year>2015</year>. Epub 2015/11/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/jnc.13415" xlink:type="simple">10.1111/jnc.13415</ext-link></comment> <object-id pub-id-type="pmid">26525923</object-id>.</mixed-citation></ref>
<ref id="pone.0208357.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Adair</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Charlie</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Dencoff</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Kaye</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Quinn</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Camicioli</surname> <given-names>RM</given-names></name>, <etal>et al</etal>. <article-title>Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease</article-title>. <source>Stroke; a journal of cerebral circulation</source>. <year>2004</year>;<volume>35</volume>(<issue>6</issue>):<fpage>e159</fpage>–<lpage>62</lpage>. Epub 2004/04/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/01.STR.0000127420.10990.76" xlink:type="simple">10.1161/01.STR.0000127420.10990.76</ext-link></comment> 01.STR.0000127420.10990.76 [pii]. <object-id pub-id-type="pmid">15105518</object-id>.</mixed-citation></ref>
<ref id="pone.0208357.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Candelario-Jalil</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Taheri</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Grossetete</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Adair</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Edmonds</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment</article-title>. <source>Stroke; a journal of cerebral circulation</source>. <year>2011</year>;<volume>42</volume>(<issue>5</issue>):<fpage>1345</fpage>–<lpage>50</lpage>. Epub 2011/04/02. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.110.600825" xlink:type="simple">10.1161/STROKEAHA.110.600825</ext-link></comment> <object-id pub-id-type="pmid">21454822</object-id>; PubMed Central PMCID: PMC3119779.</mixed-citation></ref>
<ref id="pone.0208357.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nagy</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Bozdagi</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Matynia</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Balcerzyk</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Okulski</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Dzwonek</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory</article-title>. <source>J Neurosci</source>. <year>2006</year>;<volume>26</volume>(<issue>7</issue>):<fpage>1923</fpage>–<lpage>34</lpage>. Epub 2006/02/17. doi: 26/7/1923 [pii] <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1523/JNEUROSCI.4359-05.2006" xlink:type="simple">10.1523/JNEUROSCI.4359-05.2006</ext-link></comment> <object-id pub-id-type="pmid">16481424</object-id>.</mixed-citation></ref>
<ref id="pone.0208357.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dziembowska</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Milek</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Janusz</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rejmak</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Romanowska</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Gorkiewicz</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Activity-dependent local translation of matrix metalloproteinase-9</article-title>. <source>J Neurosci</source>. <year>2012</year>;<volume>32</volume>(<issue>42</issue>):<fpage>14538</fpage>–<lpage>47</lpage>. Epub 2012/10/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1523/JNEUROSCI.6028-11.2012" xlink:type="simple">10.1523/JNEUROSCI.6028-11.2012</ext-link></comment> <object-id pub-id-type="pmid">23077039</object-id>.</mixed-citation></ref>
<ref id="pone.0208357.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vafadari</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Salamian</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kaczmarek</surname> <given-names>L</given-names></name>. <article-title>MMP-9 in translation: from molecule to brain physiology, pathology, and therapy</article-title>. <source>Journal of neurochemistry</source>. <year>2016</year>;<volume>139</volume> <issue>Suppl 2</issue>:<fpage>91</fpage>–<lpage>114</lpage>. Epub 2016/11/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/jnc.13415" xlink:type="simple">10.1111/jnc.13415</ext-link></comment> <object-id pub-id-type="pmid">26525923</object-id>.</mixed-citation></ref>
<ref id="pone.0208357.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wojcik-Stanaszek</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Sypecka</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Szymczak</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Ziemka-Nalecz</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Khrestchatisky</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Rivera</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>The potential role of metalloproteinases in neurogenesis in the gerbil hippocampus following global forebrain ischemia</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>(<issue>7</issue>):<fpage>e22465</fpage>. Epub 2011/07/30. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0022465" xlink:type="simple">10.1371/journal.pone.0022465</ext-link></comment> <object-id pub-id-type="pmid">21799862</object-id>; PubMed Central PMCID: PMCPMC3143139.</mixed-citation></ref>
<ref id="pone.0208357.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gao</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Nguyen</surname> <given-names>TT</given-names></name>, <name name-style="western"><surname>Suckow</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Wolter</surname> <given-names>WR</given-names></name>, <name name-style="western"><surname>Gooyit</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Mobashery</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Acceleration of diabetic wound healing using a novel protease-anti-protease combination therapy</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2015</year>;<volume>112</volume>(<issue>49</issue>):<fpage>15226</fpage>–<lpage>31</lpage>. Epub 2015/11/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1517847112" xlink:type="simple">10.1073/pnas.1517847112</ext-link></comment> <object-id pub-id-type="pmid">26598687</object-id>; PubMed Central PMCID: PMCPMC4679041.</mixed-citation></ref>
<ref id="pone.0208357.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gooyit</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Peng</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Wolter</surname> <given-names>WR</given-names></name>, <name name-style="western"><surname>Pi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Ding</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Hesek</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>A chemical biological strategy to facilitate diabetic wound healing</article-title>. <source>ACS Chem Biol</source>. <year>2014</year>;<volume>9</volume>(<issue>1</issue>):<fpage>105</fpage>–<lpage>10</lpage>. Epub 2013/09/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1021/cb4005468" xlink:type="simple">10.1021/cb4005468</ext-link></comment> <object-id pub-id-type="pmid">24053680</object-id>; PubMed Central PMCID: PMCPMC3947039.</mixed-citation></ref>
</ref-list>
</back>
</article>